NDAC to discuss ipecac
This article was originally published in The Tan Sheet
Executive Summary
FDA advisory committee will consider the "safety and efficacy of ipecac syrup indicated for emergency use to cause vomiting in poisoning cases for continued OTC status" during a June 12 meeting. Primary areas of consideration will be: status of the role of ipecac syrup in gastrointestinal decontamination; whether the literature clearly defines the syrup's risk/benefit ratio; the role of ipecac in poison treatment for populations with limited access to emergency medical treatment; whether there is significant abuse of ipecac; and alternative therapies to ipecac syrup, FDA says. NDAC meeting will begin at 8 a.m. at the Holiday Inn, 8120 Wisconsin Ave., Bethesda, Md...